Boryung Pharmaceutical Signs Exclusive China Sales Contract for Gelpos Worth 100.2 Billion KRW
[Asia Economy Reporter Lee Seon-ae] Boryung Pharmaceutical announced on the 17th that it has signed an exclusive sales contract with Sinopharm (a company directly under the State-owned Assets Supervision and Administration Commission of the State Council (SASAC) of China) for Boryung Pharmaceutical's Gelphos (Phosgel) in China, worth 100.2147 billion KRW. This amount corresponds to 17.84% of recent sales, and the contract period is from today until August 17, 2026.
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Koo Yoon-chul: "$10.9 Billion Inflow After WGBI Inclusion... Accelerating Reforms in Forex and Capital Markets"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
